CenterBook Partners LP Sells 2,868 Shares of Natera, Inc. $NTRA

CenterBook Partners LP lowered its holdings in Natera, Inc. (NASDAQ:NTRA) by 56.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,231 shares of the medical research company’s stock after selling 2,868 shares during the period. CenterBook Partners LP’s holdings in Natera were worth $922,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NTRA. BlackRock Inc. acquired a new stake in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. Arrowstreet Capital Limited Partnership boosted its position in Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. grew its stake in Natera by 24.1% during the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after buying an additional 227,605 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Natera by 10.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after buying an additional 80,440 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in Natera during the 2nd quarter worth $199,960,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In other news, CEO Steven Chapman sold 3,801 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. This trade represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30. Following the transaction, the chief financial officer owned 46,574 shares in the company, valued at $19,819,565.70. This represents a 3.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 47,056 shares of company stock valued at $17,760,989. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $311.98 on Wednesday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The business has a fifty day moving average of $379.93 and a 200-day moving average of $270.42.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The company had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. Natera’s revenue for the quarter was up 34.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.64) earnings per share. Analysts forecast that Natera, Inc. will post -1.20 earnings per share for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% to about $794 million, beating estimates, and Natera raised its 2026 sales outlook as test volumes—particularly oncology testing—accelerated. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Positive Sentiment: Management highlighted a long-term goal of $6 billion in revenue by 2029, supported by Signatera growth, broader reimbursement and continued investment. Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
• Positive Sentiment: Natera is collaborating with Incyte on a Phase 2 colorectal cancer trial, which could support its oncology testing business, though the commercial impact will depend on trial results and adoption. Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
• Neutral Sentiment: A report listed short interest at zero shares as of November 10, a figure that does not indicate meaningful short positioning; the report’s description of a significant increase appears inconsistent with that number.
• Negative Sentiment: Despite the revenue beat, Natera’s quarterly loss of $0.42 per share was wider than the $0.28 loss analysts expected, highlighting ongoing profitability concerns. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Negative Sentiment: Analysts cut price targets, including Robert W. Baird’s reduction to $403 from $458, while maintaining an Outperform rating. JPMorgan also reportedly lowered its target, adding a cautious note despite the improved outlook. Robert W. Baird Stock Recommendations Natera Stock Gets Price Target Cut from JPMorgan Chase & Co.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. Roth Capital started coverage on Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price on the stock. Leerink Partners set a $330.00 price target on shares of Natera in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and set a $363.50 price target on shares of Natera in a research report on Friday. BTIG Research increased their price objective on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $394.31.

Natera Company Profile

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.